JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Treatment of congenital nevi with the Q-switched Alexandrite laser.

Q-switched mode lasers have been utilized for treatment of many pigmentary lesions. Because of their short pulse durations (1-100 ns), these lasers selectively destroy pigment laden cells while sparing the surrounding normal tissues. To determine if the Q-switched alexandrite laser (QSAL) is effective in the treatment of congenital melanocytic nevi, 53 patients with these lesions were treated with QSAL; of these, 16 also received CO(2) laser treatment between QSAL treatments. We observed an average improvement score in the 53 treated patients of 2.623 + 1.13, corresponding to a 72% improvement. Treatment with the combination of QSAL and a CO(2) laser resulted in a significant enhancement of improvement score (3.06 +/- 1.18) compared to patients treated with the QSAL alone (2.43 +/- 1.07; p = 0.0393). Complications were mild, with 35 nevi (67.3%) showing textural change of skin after treatment, 2 (3.8%) showing depressed scar formation, and 4 (7.5%) showing hypertrophic changes, while 12 nevi (23%) showed no changes. Hypopigmentation was observed in 16 patients (30%), and hyperpigmentation was observed in 15 patients (28%) 48 weeks after the final QSAL treatment. Repigmentation to a brown to black spot was observed in 44/53 (83%) patients within an average of 5.45 +/- 3.93 months. These results indicate that the QSAL was as effective as other Q switch mode lasers in the treatment of congenital melanocytic nevi, but repigmentation is a problem.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app